Li Wenxi, Tian Hao, Yan Ziliang, Yu Xinying, Li Bei, Dai Yunlu
Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR 999078, China.
MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR 999078, China.
ACS Nano. 2025 Jan 14;19(1):1222-1237. doi: 10.1021/acsnano.4c13388. Epub 2024 Dec 19.
More than the sparse infiltration in glioblastoma, cytotoxic T lymphocytes (CTLs) also function inefficiently and overexpress the inhibitory markers, especially the identified NK cell receptor (NK1.1). However, most studies solely focus on how to augment tumor-infiltrating CTLs and overlook their killing maintenance. Metalloimmunotherapy has been proven to improve the functionalities of CTLs, but it has barely adapted to glioblastoma due to the severe limitations of safe delivery and the brain's physiological properties. Herein, we synthesized an amphipathic polyethylene glycol (PEG) polymer (designated as MPP) modified with the choline analogue 2-methacryloyloxyethyl phosphorylcholine (MPC) and polyphenol moieties to customize a nanoeditor (Mg@MK-8931@MPP) by coordinating Mg and entrapping the hydrophobic BACE1 inhibitor MK-8931, then precisely redressing the gliomatous CTL sparsity and cytotoxic dysfunction. Upon MPC-assisted local accumulation in glioblastoma, Mg@MK-8931@MPP nanoeditors release MK-8931 to repolarize M2-like macrophages, facilitating CTL infiltration quantitatively. The cenogenetic immune adjuvant Mg ulteriorly fortifies the T-cell receptor downstream signals to enhance the functionality of the ingoing CTLs in quality, leading to the secretion of high-level antitumor cytokines and cytotoxic proteins. Further blocking the inhibitory NK1.1 on CTLs by anti-NK1.1 antibodies can extend their cytolytic endgame. Studies on T-cell-deficient and wild-type mouse models support the immunomodulating feasibility of Mg@MK-8931@MPP. This gliomatous CTL-tailored strategy concurrently broadens metalloimmunotherapy to glioblastoma treatment and highlights the necessity of enforcing gliomatous CTLs' functionality.
与胶质母细胞瘤中稀疏的浸润情况相比,细胞毒性T淋巴细胞(CTLs)的功能也存在缺陷,并且过度表达抑制性标志物,尤其是已确定的自然杀伤细胞受体(NK1.1)。然而,大多数研究仅关注如何增加肿瘤浸润性CTLs,而忽视了它们的杀伤维持能力。金属免疫疗法已被证明可改善CTLs的功能,但由于安全递送的严重限制和大脑的生理特性,它几乎未应用于胶质母细胞瘤。在此,我们合成了一种用胆碱类似物2-甲基丙烯酰氧基乙基磷酰胆碱(MPC)和多酚部分修饰的两亲性聚乙二醇(PEG)聚合物(命名为MPP),通过配位镁并包裹疏水性β-分泌酶1抑制剂MK-8931来定制一种纳米编辑器(Mg@MK-8931@MPP),然后精确纠正胶质母细胞瘤中CTLs的稀疏性和细胞毒性功能障碍。在MPC辅助下,Mg@MK-8931@MPP纳米编辑器在胶质母细胞瘤中局部聚集,释放MK-8931使M2样巨噬细胞重新极化,定量促进CTLs浸润。遗传免疫佐剂镁进一步增强T细胞受体下游信号,从质量上提高进入的CTLs的功能,导致高水平抗肿瘤细胞因子和细胞毒性蛋白的分泌。用抗NK1.1抗体进一步阻断CTLs上的抑制性NK1.1可延长其溶细胞终局。对T细胞缺陷和野生型小鼠模型的研究支持了Mg@MK-8931@MPP的免疫调节可行性。这种针对胶质母细胞瘤中CTLs的策略同时将金属免疫疗法扩展到胶质母细胞瘤治疗,并突出了增强胶质母细胞瘤中CTLs功能的必要性。